Risperidone versus zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity: A long-term randomized, controlled, crossover study

European Journal of Psychiatry

Volumn 20, Issue 3, 2006, Pages 133-146

  Rubioz, Gabriel ^a,e   Martíne, Isabel ^a   Recio, Ana ^b   Ponce, Guillermo ^c   López Muñoz, Francisco ^d   Alamo, Cecilio ^d   Jiménez Arriero, Miguel Ángel ^c   Palomo, Tomás ^c  

^a Retiro Mental Health Service   (Spain)

^b Mental Health Centre of Ciudad Lineal   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d UNIVERSITY OF ALCALÁ   (Spain)

^e Alcoholism Research Program   (Spain)

Author keywords

Dual diagnosis; Risperidone; Schizophrenia; Substance use disorders; Zuclopenthixol

Indexed keywords

ANTIPARKINSON AGENT; CHLORPROMAZINE; HALOPERIDOL; RISPERIDONE; ZUCLOPENTHIXOL;

ADULT; AGED; ALCOHOLISM; ARTICLE; CANNABIS ADDICTION; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COCAINE DEPENDENCE; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT EDUCATION; POSITIVE AND NEGATIVE SYNDROME SCALE; PROGNOSIS; PSYCHIATRIC DIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SUBSTANCE ABUSE; SYMPTOMATOLOGY; TREATMENT OUTCOME; URINALYSIS;

EID: 33746740638     PISSN: 02136163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area Study. JAMA 1990; 264: 2511-2518.
2. Kavanagh DJ, McGrath J, Saunders JB, et al. Substance Misuse in patients with schizophrenia: epidemiology and management. Drugs 2002; 62: 743-755.
3. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994; 51: 273-279.
4. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res 1999; (Supp 35): s93-s100.
5. Rubio G. Métodos diagnósticos de trastornos psiquiátricos en poblaciones con abuso de drogas. In: Cabrera J ed. Patología Dual. Madrid: Agencia Antidroga; 1998. p. 18-31
6. Rubio G, Casas M. Revisión del tratamiento de la esquizofrenia en individuos con abuso de drogas. Actas Esp Psiquiatr 2001; 29: 124-130.
7. Smelson DA, Losonczy MF, Davis CW, Kaune M, Williams J, Ziedonis D. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Can J Psychiatry 2002; 47: 671-675.
8. Ziedonis DM, Trudeau K. Motivation to Quit Using Substances Among Individuals With Schizophrenia: Implications for a Motivation-Based Treatment Model. Schizophr Bull 1997; 23: 229-238.
9. Kane JM, Leucht S, Carpenter D, Docherty JP. The expert Consensus Guideline of Psychotic Disorders. Optimizing Pharmacologic Treatment of Psychotic Disorders. J Clin Psychiatry 2003; 64 (suppl 12): s1-s97.
10. Huang CC. Risperdal reduces alcohol use in dual disabled schizophrenia patients. Eur Neuropsychopharmacol 1996; 6 (suppl. 3): s43.
11. Casas M, Gutierrez M, Gibert J, Bobes J, Roncero C, Octavio I. Risperidona en el tratamiento de pacientes psicóticos con abuso y dependencia de opiáceos. Actas Esp Psiquiatr 2001; 29: 380-385.
12. Kingstone E, Kolivakis T, Kossatz I. [Double-blind study of clopenthixol and chlorpromazine in acute hospitalized schizophrenics]. Int Z Klin Pharmakol Ther Toxikol 1970; 3(1): 41-45
13. Huttunen MO, Piepponen T, Rantanen H, Larmo I, Nyholm R, Raitasuo V. Risperidone versus Zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatr Scand 1995; 91: 271-277.
14. Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment opinion. J Clin Psychiatry 1992; 53: 426-433.
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th ed.). Washington DC: APA; 1994.
16. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale for Schizophrenia. Schizophr Bull 1987; 13: 261-276.
17. Guy W . ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Rockville: US Department of Health, Education and Welfare; 1976. p. 217-222.
18. McLellan AT, Luborsky L, Woody GE, O'Brien CP. An improved diagnostic evaluation instrument for substance abuse patients: the Addiction Severity Index. J Nerv Men Dis 1980; 168, 26-33.
19. Chouinard G, Ross-Chouinard A, Annable L, Jones BD. The Extrapyramidal Symptom Rating Scale. Can J Neurol Sci 1980; 7: 233.
20. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. Acta Psychiatr Scand 1987; 76 (suppl 334): s81-s94.
21. Roberts LJ, Shaner A, Eckman TA eds. Overcoming addictions. Skills training for people with schizophrenia. New York: W. W. Norton & Company; 1999.
22. Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993; 88: 395-402.
23. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825-835.
24. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel group study versus haloperidol. Br J Psychiatry 1995; 166: 712-726.
25. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factors analysis: combined results of the North American Trial. J Clin Psychiatry 1997; 58: 538-546.
26. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996; 124: 57-73.
27. Yoshimura R, Nakamura J, Ueda N, Terao T. Effect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9- hydroxyrisperidone, pMHPG levels, and clinical improvement. Int Clin Psychopharmacol 2000; 15: 175-180.
28. Möller HJ, Müller H, Borison RL, Schooler NR, Chouinard G. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. Eur Arch Psychiatr Clin Neurosci 1995; 245: 45-49.
29. Möller HJ, Müller H. Statistical differentiation between direct and indirect effects of neuroleptics on negative symptoms. Eur Arch Psychiatr Clin Neurosci 1997; 247: 1-5.
30. Davis JM, Chen N. Clinical profile of an atypical antipsychotic: risperidone. Schizophr Bull 2002; 28: 43-61.
31. Smelson DA, Roy A, Roy M. Risperidone and neuropsychological test performance in cocaine-withdrawn patients. Can J Psychiatry 1997; 42: 431.
32. Buckley P, Thompson PA, Way L, Meltzer HY. Substance abuse among patients with treatment-resistant schizophrenia: Characteristics and implications for clozapine. Am J Psychiatry 1994; 151: 385-389.
33. Conley R, Gale E, Hirsch K. Olanzapine response in therapy-refractory schizophrenia with substance abuse. Schizophr Res 1998; 33: 95-101.
34. McEvoy J, Freudenreich O, McGree M. Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry 1995; 37: 550-552
35. Brunette LM, Mueser KT, Xie H, Drake RE. Relationships between symptoms of schizophrenia and substance abuse. J Nerv Ment Dis 1997; 185: 13-20.
36. Zimmet SV, Strous RD, Burgess ES, Kohnstamm S, Green AL. Effects of clozapine on substance use in patients with schizophrenia and psychoaffective disorders: A retrospective survey. J Clin Psychopharmacol 2000; 20: 94-98.
37. Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among schizophrenic patients. Schizophr Bull 2000; 26: 441-449.
38. Marchi M, Raiteri M. Nicotine autoreceptors mediating enhancement of acetylcholine release become operative in conditions of impaired cholinergic presynaptic function. J Neurochem 1996; 67: 1974-1981.
39. Green AI, Zimmer SV, Strous RD, Schilkraut JJ. Clozapine for comorbid substance use disorder and schizophrenia: Do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine. Harv Rev Psychiatry 1999; 6: 287-296.
40. Rubio G, Jiménez- Arriero MA, Manzanares J, Ponce G, Palomo T. Tratamiento farmacológico de la esquizofrenia en pacientes con abuso/dependencia de drogas. In: Rubio G, Hernández JA, Jiménez-Arriero MA, Palomo T eds. Guía para el tratamiento de los pacientes con esquizofrenia. Madrid: Fundación Cerebro y Mente; 2002. p. 219-244.
41. Hutchison KE, Swift R, Rohsenow DJ, Monti PM, Davidson D, Almeida R. Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. Psychopharmacology 2001; 155: 27-34.
42. Newton TF, Ling W, Kalechstein A, Uslaner J, Tervo K. Risperidone pre-treatment reduces the euphoric effects of experimentally administered cocaine. Psychiat Res 2001; 102: 227-233.
43. See RE, Aravagiri M, Ellison GD. Chronic neuroleptic treatment in rats produces persisting changes in GABA-A and dopamine D-2, but not dopamine D-1, receptors. Life Sci 1989; 44: 229-236.
44. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991; 41: 1-24.
45. Durell J, Lechtenberg B, Corse S, Frances R. Intensive case management of persons with chronic mental illness who abuse substances. Hosp Comm Psychiatr 1993; 44: 415-416.
46. Jerrell JM, Ridgley MS. Comparative effectiveness of three approaches to serving people with severe mental illness and substance use disorders. J Nerv Ment Dis 1995; 183: 566-576.
47. Mueser KT, Valentier DP, Agresta J. Coping with negative symptoms of schizophrenia: Patient and familiy perspectives. Schizophr Bull 1997; 23; 329-339.
48. Fridell M. Psychosocial Treatment for Drug Dependence. In: Beglund M, Thelander S, Jonsson E, eds. Treating Alcohol and Drug Abuse. Weinheim: Wiley-VC; 2003. p. 325-413.
49. Rubio G, Jiménez-Arriero MA, Ponce G, Palomo T. Naltrexone versus Acamprosate: 1 year follow-up alcohol dependence treatment. Alcohol Alcoholism 2001; 36: 419-425.